GSK's B7-H3-Targeted Antibody-Drug Conjugate, GSK'227, Receives EMA Priority Medicines Designation in Relapsed Extensive-Stage Small-Cell Lung Cancer
December 18, 2024
December 18, 2024
LONDON, England, Dec. 18 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 16, 2024:
* * *
- Regulatory designation based on promising preliminary clinical data
- PRIME Designation granted to medicines with potential to address significant unmet medical needs
- Extensive-stage small-cell lung cancer is associated with high rates of relapse, few treatment options and poor prognosis . . .
* * *
- Regulatory designation based on promising preliminary clinical data
- PRIME Designation granted to medicines with potential to address significant unmet medical needs
- Extensive-stage small-cell lung cancer is associated with high rates of relapse, few treatment options and poor prognosis . . .